The Intersection of Chronic Obstructive Pulmonary Disease and Cardiovascular Disease: Recent Insights in a Challenging Area

IF 2.5 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Michael Heffernan MD, PhD, FRCPC, FACC , Samantha Rutherford BHSc
{"title":"The Intersection of Chronic Obstructive Pulmonary Disease and Cardiovascular Disease: Recent Insights in a Challenging Area","authors":"Michael Heffernan MD, PhD, FRCPC, FACC ,&nbsp;Samantha Rutherford BHSc","doi":"10.1016/j.cjco.2025.01.001","DOIUrl":null,"url":null,"abstract":"<div><div>Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) are 2 prevalent and interconnected health conditions that have a significant global impact. COPD is characterized by airflow obstruction and is caused by smoking and/or environmental factors. COPD is associated with chronic inflammation and structural changes in the airways and lung parenchyma. CVD encompasses various cardiac and vascular conditions and is a leading global cause of mortality, with risk factors that include diabetes, smoking, and dyslipidemia. CVDs discussed in this review, in relation to COPD, include hypertension, coronary artery disease and ischemic heart disease, heart failure, cardiac arrhythmias, and cerebrovascular disease. The interplay between COPD and CVD is evident, with shared risk factors and physiological mechanisms contributing to their frequent comorbidity. Therefore, an integrated approach to care involving primary care physicians, respirologists, and cardiologists is essential to effectively manage the dual burden of COPD and CVD.</div><div>This review outlines the shared risks and underlying mechanisms of these conditions, their diagnosis, and the clinical implications of dual COPD and CVD in a patient, including how COPD exacerbations significantly elevate the risk of cardiovascular (CV) events and mortality. Pharmacologic CVD and COPD therapies, as well as their CV and respiratory effects, are discussed. Key trials (Towards a Revolution in COPD Health [TORCH]; Study to Understand Mortality and Morbidity in COPD [SUMMIT]; InforMing the Pathway of COPD Treatment [IMPACT]; and <strong>E</strong>fficacy and Safety of Triple <strong>Th</strong>erapy in <strong>O</strong>bstructive Lung Di<strong>s</strong>ease [ETHOS]) are discussed that demonstrate the effectiveness of triple bronchodilator therapy in reducing exacerbation rates, as well as all-cause and cardiovascular mortality in patients with COPD and CVD. Overall, this review highlights the need for an integrated approach to patient management, involving collaboration among primary care physicians, respirologists, and cardiologists, to effectively address the dual burden of these diseases.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 4","pages":"Pages 493-507"},"PeriodicalIF":2.5000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CJC Open","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2589790X25000010","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) are 2 prevalent and interconnected health conditions that have a significant global impact. COPD is characterized by airflow obstruction and is caused by smoking and/or environmental factors. COPD is associated with chronic inflammation and structural changes in the airways and lung parenchyma. CVD encompasses various cardiac and vascular conditions and is a leading global cause of mortality, with risk factors that include diabetes, smoking, and dyslipidemia. CVDs discussed in this review, in relation to COPD, include hypertension, coronary artery disease and ischemic heart disease, heart failure, cardiac arrhythmias, and cerebrovascular disease. The interplay between COPD and CVD is evident, with shared risk factors and physiological mechanisms contributing to their frequent comorbidity. Therefore, an integrated approach to care involving primary care physicians, respirologists, and cardiologists is essential to effectively manage the dual burden of COPD and CVD.
This review outlines the shared risks and underlying mechanisms of these conditions, their diagnosis, and the clinical implications of dual COPD and CVD in a patient, including how COPD exacerbations significantly elevate the risk of cardiovascular (CV) events and mortality. Pharmacologic CVD and COPD therapies, as well as their CV and respiratory effects, are discussed. Key trials (Towards a Revolution in COPD Health [TORCH]; Study to Understand Mortality and Morbidity in COPD [SUMMIT]; InforMing the Pathway of COPD Treatment [IMPACT]; and Efficacy and Safety of Triple Therapy in Obstructive Lung Disease [ETHOS]) are discussed that demonstrate the effectiveness of triple bronchodilator therapy in reducing exacerbation rates, as well as all-cause and cardiovascular mortality in patients with COPD and CVD. Overall, this review highlights the need for an integrated approach to patient management, involving collaboration among primary care physicians, respirologists, and cardiologists, to effectively address the dual burden of these diseases.
慢性阻塞性肺疾病和心血管疾病的交叉:在一个具有挑战性的领域的最新见解
慢性阻塞性肺疾病(COPD)和心血管疾病(CVD)是两种普遍存在且相互关联的健康状况,具有重大的全球影响。COPD以气流阻塞为特征,由吸烟和/或环境因素引起。慢性阻塞性肺病与气道和肺实质的慢性炎症和结构改变有关。心血管疾病包括各种心脏和血管疾病,是全球主要的死亡原因,其危险因素包括糖尿病、吸烟和血脂异常。本文讨论的与慢性阻塞性肺病相关的心血管疾病包括高血压、冠状动脉疾病和缺血性心脏病、心力衰竭、心律失常和脑血管疾病。慢性阻塞性肺病和心血管疾病之间的相互作用是显而易见的,共同的危险因素和生理机制导致了它们频繁的合并症。因此,包括初级保健医生、呼吸科医生和心脏病专家在内的综合护理方法对于有效管理慢性阻塞性肺病和心血管疾病的双重负担至关重要。这篇综述概述了这些疾病的共同风险和潜在机制、诊断和双重COPD和CVD患者的临床意义,包括COPD加重如何显著提高心血管事件和死亡率的风险。药物CVD和COPD治疗,以及他们的CV和呼吸的影响,进行了讨论。迈向COPD健康革命的关键试验[TORCH];慢性阻塞性肺病死亡率和发病率研究[SUMMIT];告知COPD治疗途径[IMPACT];以及三联治疗对阻塞性肺疾病的疗效和安全性[ETHOS])进行了讨论,证明了三联支气管扩张剂治疗在降低COPD和CVD患者的加重率以及全因死亡率和心血管死亡率方面的有效性。总的来说,这篇综述强调了对患者管理的综合方法的需要,包括初级保健医生、呼吸科医生和心脏病专家之间的合作,以有效地解决这些疾病的双重负担。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CJC Open
CJC Open Medicine-Cardiology and Cardiovascular Medicine
CiteScore
3.30
自引率
0.00%
发文量
143
审稿时长
60 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信